Back to top
more

MEDIVATION INC (MDVN)

(Delayed Data from NSDQ)

$81.44 USD

81.44
7,190,229

+0.02 (0.03%)

Updated Sep 27, 2016 04:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

[MDVN]

Reports for Purchase

Showing records 1 - 20 ( 252 total )

Industry: Medical - Biomedical and Genetics

Record: 1

09/23/2016

Industry Report

Pages: 16

Recent Drug Launch Weekly Retail Sales Tracker

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

09/16/2016

Industry Report

Pages: 16

Recent Drug Launch Weekly Retail Sales Tracker- Week Ended Sept. 9

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

09/12/2016

Company Report

Pages: 8

Price: 24.95

Industry: Medical - Biomedical and Genetics

Record: 4

09/02/2016

Industry Report

Pages: 16

Biotechnology/Biopharmaceuticals - Recent Drug Launch Weekly Retail Sales Tracker- Week Ended Aug 26

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

08/23/2016

Company Report

Pages: 2

Deal Overview

Provider: G.RESEARCH, LLC

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

08/22/2016

Company Report

Pages: 6

Downgrading to NEUTRAL; Pfizer to Buy MDVN for ~$14B, Raising PT to $81.50

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

08/22/2016

Industry Report

Pages: 16

Biopharmaceuticals - Recent Drug Launch Weekly Retail Sales Tracker- Week Ended Aug 12

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

08/09/2016

Company Report

Pages: 7

Q2 EPS; Reaffirming Financial Guidance Ahead of TERRAIN PDUFA; Reiterate OUTPERFORM and $66 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

08/09/2016

Company Report

Pages: 8

Price: 24.95

Industry: Medical - Biomedical and Genetics

Record: 10

07/29/2016

Company Report

Pages: 7

Astellas Reports 2Q Xtandi Sales In-Line with Expectations, Reiterate OP

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

07/29/2016

Industry Report

Pages: 16

Recent Drug Launch Weekly Retail Sales Tracker- Week Ended July 22

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

07/11/2016

Company Report

Pages: 8

2Q Preview; Xtandi Script Growth Trends and Other Developments, Raising PT to $66 and Reiterating O

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

07/08/2016

Company Report

Pages: 7

Price: 24.95

Industry: Medical - Biomedical and Genetics

Record: 14

07/07/2016

Company Report

Pages: 2

We believe Medivation continues to be a buyout target.

Provider: G.RESEARCH, LLC

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 15

07/05/2016

Company Report

Pages: 8

Price: 24.95

Industry: Medical - Biomedical and Genetics

Record: 16

07/01/2016

Industry Report

Pages: 16

Recent Drug Launch Weekly Retail Sales Tracker- Week Ended June 24

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 17

06/24/2016

Industry Report

Pages: 17

Recent Drug Launch Weekly Retail Sales Tracker- Week Ended June 17

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 18

06/03/2016

Company Report

Pages: 8

Price: 24.95

Industry: Medical - Biomedical and Genetics

Record: 19

05/27/2016

Industry Report

Pages: 17

Recent Drug Launch Weekly Retail Sales Tracker - Week Ended May 20

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 20

05/20/2016

Industry Report

Pages: 17

Recent Drug Launch Weekly Retail Sales Tracker - Week Ended May 13

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party
// eof